465 related articles for article (PubMed ID: 28041858)
1. Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement.
Stolker JM; Cohen DJ; Kennedy KF; Pencina MJ; Arnold SV; Kleiman NS; Spertus JA;
Cardiovasc Revasc Med; 2017; 18(3):169-176. PubMed ID: 28041858
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries.
Yoshida T; Sakata K; Nitta Y; Taguchi T; Kaku B; Katsuda S; Shimojima M; Gamou T; Nakahashi T; Konno T; Kawashiri MA; Yamagishi M; Hayashi K
Heart Vessels; 2016 May; 31(5):635-42. PubMed ID: 25758470
[TBL] [Abstract][Full Text] [Related]
3. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
6. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
[TBL] [Abstract][Full Text] [Related]
7. Long-term clinical and angiographic outcomes of percutanenous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy.
Cheng R; Vanichsarn C; Patel JK; Currier J; Chang DH; Kittleson MM; Makkar R; Kobashigawa JA; Azarbal B
Catheter Cardiovasc Interv; 2017 Jul; 90(1):48-55. PubMed ID: 27862865
[TBL] [Abstract][Full Text] [Related]
8. Predictors and variability of drug-eluting vs bare-metal stent selection in contemporary percutaneous coronary intervention: Insights from the PRISM study.
Shafiq A; Gosch K; Amin AP; Ting HH; Spertus JA; Salisbury AC
Clin Cardiol; 2017 Aug; 40(8):521-527. PubMed ID: 28300284
[TBL] [Abstract][Full Text] [Related]
9. Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.
Stolker JM; Cohen DJ; Kennedy KF; Pencina MJ; Lindsey JB; Mauri L; Cutlip DE; Kleiman NS;
Circ Cardiovasc Interv; 2012 Dec; 5(6):772-82. PubMed ID: 23093553
[TBL] [Abstract][Full Text] [Related]
10. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
11. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
12. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
[TBL] [Abstract][Full Text] [Related]
13. In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
Tolerico PH; Cohen DJ; Kleiman NS; Berger PB; Brilakis ES; Piana RN; Shammo S; Keyes MJ; Kennedy KF; Massaro JM; Saucedo JF;
Catheter Cardiovasc Interv; 2012 Dec; 80(7):1127-36. PubMed ID: 22431166
[TBL] [Abstract][Full Text] [Related]
14. Angiographic predictors of 2-year stent thrombosis in patients receiving drug-eluting stents: Insights from the ADAPT-DES study.
Généreux P; Redfors B; Witzenbichler B; Maehara A; Yadav M; Weisz G; Francese DP; Parvataneni R; Brener SJ; Mehran R; Kirtane AJ; Stone GW
Catheter Cardiovasc Interv; 2017 Jan; 89(1):26-35. PubMed ID: 26813732
[TBL] [Abstract][Full Text] [Related]
15. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
[TBL] [Abstract][Full Text] [Related]
16. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
Kandzari DE; Leon MB; Meredith I; Fajadet J; Wijns W; Mauri L
JACC Cardiovasc Interv; 2013 May; 6(5):504-12. PubMed ID: 23602459
[TBL] [Abstract][Full Text] [Related]
17. Transition from bare metal to drug eluting stenting in contemporary US practice: effect on incidence and predictors of clinically driven target lesion revascularization.
Jonas M; Resnic FS; Levin AD; Arora N; Rogers CD
Catheter Cardiovasc Interv; 2007 Aug; 70(2):175-83. PubMed ID: 17630659
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
[TBL] [Abstract][Full Text] [Related]
19. Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry.
Jensen JK; Jensen LO; Terkelsen CJ; Lassen JF; Tilsted HH; Hansen KN; Maeng M; Thuesen L; Thayssen P
Catheter Cardiovasc Interv; 2013 Feb; 81(2):260-5. PubMed ID: 22511512
[TBL] [Abstract][Full Text] [Related]
20. Drug-eluting stents in patients on chronic hemodialysis: paclitaxel-eluting stents vs. limus-eluting stents.
Sardi GL; Loh JP; Torguson R; Laynez-Carnicero A; Kitabata H; Xue Z; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2014 Mar; 15(2):86-91. PubMed ID: 24684759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
